-
Cerebrovascular diseases · Jan 2018
Black Hole Sign Predicts Poor Outcome in Patients with Intracerebral Hemorrhage.
- Qi Li, Wen-Song Yang, Sheng-Li Chen, Fu-Rong Lv, Fa-Jin Lv, Xi Hu, Dan Zhu, Du Cao, Xing-Chen Wang, Rui Li, Liang Yuan, Xin-Yue Qin, and Peng Xie.
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Cerebrovasc. Dis. 2018 Jan 1; 45 (1-2): 48-53.
BackgroundIn spontaneous intracerebral hemorrhage (ICH), black hole sign has been proposed as a promising imaging marker that predicts hematoma expansion in patients with ICH. The aim of our study was to investigate whether admission CT black hole sign predicts hematoma growth in patients with ICH.MethodsFrom July 2011 till February 2016, patients with spontaneous ICH who underwent baseline CT scan within 6 h of symptoms onset and follow-up CT scan were recruited into the study. The presence of black hole sign on admission non-enhanced CT was independently assessed by 2 readers. The functional outcome was assessed using the modified Rankin Scale (mRS) at 90 days. Univariate and multivariable logistic regression analyses were performed to assess the association between the presence of the black hole sign and functional outcome.ResultsA total of 225 patients (67.6% male, mean age 60.3 years) were included in our study. Black hole sign was identified in 32 of 225 (14.2%) patients on admission CT scan. The multivariate logistic regression analysis demonstrated that age, intraventricular hemorrhage, baseline ICH volume, admission Glasgow Coma Scale score, and presence of black hole sign on baseline CT independently predict poor functional outcome at 90 days. There are significantly more patients with a poor functional outcome (defined as mRS ≥4) among patients with black hole sign than those without (84.4 vs. 32.1%, p < 0.001; OR 8.19, p = 0.001).ConclusionsThe CT black hole sign independently predicts poor outcome in patients with ICH. Early identification of black hole sign is useful in prognostic stratification and may serve as a potential therapeutic target for anti-expansion clinical trials.© 2018 S. Karger AG, Basel.
Notes